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SYNOPSIS
Probiotics are live microorganisms intended to provide health benefi ts when consumed (1). Typi-
cally, the endpoint in randomized controlled trials 
of probiotics has been the prevention of diarrhea or 
faster alleviation of diarrhea symptoms (2). Regard-
ing their safety, serious adverse effects have been rare 
in probiotic studies (3). However, the adverse effects 
have not been fully reported (4). In 1 trial in which a 
multispecies probiotic preparation was given to pa-
tients who had severe acute pancreatitis, the mortal-
ity rate was higher in the probiotic arm (5). Never-
theless, the use of probiotics is common. According 
to the 2012 National Health Interview Survey in the 
United States, 1.6% of adults had used prebiotics or 
probiotics in the preceding 30 days (6).
Saccharomyces cerevisiae var. boulardii is a yeast 
that is used as a probiotic. In hospitals in the United 
States, the use of S. cerevisiae var. boulardii has been 
common, especially among elderly patients (7). This 
strain is diffi cult to distinguish microbiologically 
from S. cerevisiae because they have >99% genomic 
relatedness (8). Thus, in everyday clinical laboratory 
work, the S. cerevisiae var. boulardii strain is identifi ed 
as either Saccharomyces sp. or S. cerevisiae. A review 
from 2005 considered S. cerevisiae var. boulardii to be 
the etiologic agent of Saccharomyces fungemia if the 
patient received treatment with a probiotic contain-
ing S. cerevisiae var. boulardii or if a molecular typing 
method confi rmed the identifi cation of this yeast (9). 
The authors found 37 cases in the literature. We found 
an additional 14 reports, including 22 cases of Saccha-
romyces fungemia with the same diagnostic method 
published after this review (10–23). Thus, before our 
study, 59 cases of fungemia with a link to the use of 
the probiotic had been published. All of these cases 
have been either individual cases or small cases series 
(<7 cases) without any systematic approach to quan-
tify the problem.
Furthermore, besides fungemia, there are few 
reports on other clinically relevant microbiological 
fi ndings for this yeast (i.e., in abscesses, ascites fl uid, 
or the pleural cavity). The meta-analysis we men-
tion listed 20 cases of fi ndings other than fungemia 
(9). These fi ndings are useful because they might also 
lead to a change in antimicrobial treatment.
We conducted a retrospective registry study (case 
series) at 5 university hospitals in Finland to evaluate 
the use of the S. cerevisiae var. boulardii probiotic in 
patients who had Saccharomyces fungemia or another 
clinical culture fi nding for this yeast. To evaluate the 
association between probiotic use and subsequent 
fi ndings, we compared use of S. cerevisiae var. bou-
lardii for patients who had a Saccharomyces infection 
with use of S. cerevisiae var. boulardii for patients who 
had an infection caused by another etiologic agent, 
such as bacteria or Candida sp.
Methods
Background
Finland has 5 university hospitals that are secondary 
referral centers of their catchment areas and tertiary 
referral centers for other hospital districts. Their com-
bined catchment areas cover more than half popula-
tion of Finland (3.29 million of 5.6 million persons). 
All university hospitals use the same register (SAI-
registry; Neotide Ltd, https://www.neotide.fi ), in 
which the local clinical microbial laboratory data are 
collected. These data cover all blood culture data and 
most of all other clinical microbial culture data of the 
catchment area of the university hospital.
Patient Data
At least 1 infectious diseases specialist in every uni-
versity hospital collected the clinical data from the 
medical records for all blood culture-positive cases 
found in the register that were identifi ed as Saccha-
romyces sp. or S. cerevisiae. The use of the S. cerevisiae 
var. boulardii probiotic was defi ned as use at the time 
of the positive culture or in the preceding 7 days. 
Data were collected on use during the preceding 3 
months. If the medical record was not available, the 
case-patient was classifi ed as not using a probiotic. 
The Quick SOFA score and the defi nition of septic 
shock were based on the Sepsis–3 defi nitions (24). 
The McCabe score was determined as reported by 
McCabe and Jackson (25). Data collected for case-
patients who had nonblood cultures were age, sex, 
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Because of widespread use of probiotics, their safety 
must be guaranteed. We assessed use of Saccharo-
myces boulardii probiotic yeast from medical records 
for patients who had Saccharomyces fungemia or other 
clinical Saccharomyces culture fi ndings. We evaluated 
all Saccharomyces sp. fi ndings at 5 university hospitals 
in Finland during 2009–2018. We found 46 patients who 
had Saccharomyces fungemia; at least 20 (43%) were 
using S. boulardii probiotic. Compared with a control 
group that had bacteremia or candidemia, the odds ratio 
for use of an S. boulardii probiotic was 14 (95% CI 4–44). 
Of 1,153 nonblood culture fi ndings, the history for 125 
patients was checked; at least 24 (19%) were using the 
probiotic (odds ratio 10, 95% CI 3–32). This study adds 
to published fungemia cases linked to use of S. boulardii 
probiotic and sheds light on the scale of nonblood Sac-
charomyces culture fi ndings that are also linked to use of 
this probiotic.
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malignancy, digestive tract disease, use of probiot-
ics, use of antifungal medication at the time of the 
culture, and possible change of medication resulting 
from finding of Saccharomyces sp. The most recent 
25 cases of nonblood culture findings in each hospi-
tal district were evaluated (excluding case-patients 
who had positive fecal samples). Isolates were ob-
tained from routine laboratory bacterial and fun-
gal cultures. The anatomic site of the culture was 
collected from the local hospital microbial registry 
(SAI) for all culture-positive cases. Abdominal sites 
were those in which culture was taken from, for ex-
ample, ascites fluid, a biliary drainage catheter, or 
abscess drainage fluid, but not from skin or wound 
secretions. Oral and respiratory tract samples were 
from sinus drainage, bronchial lavage cultures, and 
pleural drainage. Other sites included samples from 
perianal abscesses, mediastinum, and urine.
Control Group
To evaluate the practice of probiotic use in the hos-
pital ward in which the patient who had a Saccharo-
myces finding was given treatment, a control group 
was obtained from the same SAI register. For ev-
ery Saccharomyces fungemia case-patient, 2 blood 
culture-positive patients (1 chronologically closest 
before and 1 after) from the same ward as the case 
were selected. For every clinical culture sample (oth-
er than blood), there was 1 chronologically closest 
positive culture sample from the same ward as the 
case-patient who served as a control. Data collected 
for the controls were date, ward, microbe, age, sex, 
malignancy, digestive tract disease, and S. cerevisiae 
var. boulardii probiotic use at the time of the positive 
culture or in the previous 3 months.
Statistical Analysis
We used SPSS version 22.0 software (IBM Corp., 
https://www.ibm.com) for statistical analyses. The 
study was centrally approved by the Ethics Commit-
tee of Tampere University Hospital, Tampere, Finland. 
The requirement for informed consent was waived.
Results
Blood Cultures
There were 46 patients with a positive blood culture 
for Saccharomyces in the 5 hospitals during between 
January 2009–December 2018. The median age of 
case-patients was 68 (range 30–93) years and a male 
predominance (63%). The most common underly-
ing condition was a digestive tract disease (59%). 
There was a medical record confirming the use of the 
S. cerevisiae var. boulardii probiotic on the day of the 
blood culture or during the preceding 7 days for 20 
case-patients (43%). Medical records were not avail-
able for 10 case-patients (22%), and these were clas-
sified as nonusers.
Of the 20 case-patients, 17 were using S. cerevi-
siae var. boulardii probiotic on the day of the blood 
culture and 3 case-patients had already stopped us-
ing it (2 patients on the day before and 1 patient 5 
days earlier). Five additional case-patients had used 
the probiotic in the preceding 3 months, of whom 1 
patient had already stopped using it 26 days earli-
er. For 4 case-patients, the time when the use of the 
probiotic was terminated could not be determined. 
Most case-patients (16/20, 80%) received the S. cere-
visiae var. boulardii probiotic in the hospital, 3 case-
patients in some other facility, and 1 case-patient was 
using it at home. All S. cerevisiae var. boulardii pro-
biotics found in the medical records were from the 
same strain (Precosa; Biocodex Ltd., https://www.
biocodex.com). We provide characteristics, under-
lying diseases, and severity of the disease for these 
patients (Table 1, https://wwwnc.cdc.gov/EID/
article/27/8/21-0018-T1.htm; Table 2).
Antimicrobial drugs were commonly used by 
the patients (72%) during 4 weeks preceding the 
fungemia. Antifungal treatment was commenced or 
changed because of Saccharomyces fungemia for 23 
patients (50%). For an additional 8 patients (17%), the 
culture result came after the patient had died. Case-
fatality rates by day 7 were 22% (10 patients) and by 
day 28 were 37% (17 patients). Of patients who died 
by day 28, 6 patients had an ultimately fatal disease 
(McCabe score 2) and 5 patients had a rapidly fatal 
disease (McCabe score 3).
Nonblood Cultures
There were 1,153 nonblood Saccharomyces culture 
findings (fecal samples excluded). There was consid-
erable variation between hospital districts in num-
bers of the microbial cultures and anatomic sites from 
which cultures were obtained (Table 3). We evalu-
ated use of probiotics for 125 case-patients. Medi-
cal records were not available for 6 of them. Use of 
S. cerevisiae var. boulardii probiotic was confirmed 
for 24 case-patients (19%). This finding was divided 
by the anatomic site as follows: 17 (21%) of 82 from 
the abdominal region, 4 (13%) of 30 from the oral or 
respiratory tract, and 3 (23%) of 13 from other sites. 
Antifungal medication was already in use at the time 
of culture for 38% (47/125, the medical record was 
not available for 1 case-patient) of the case-patients. 
This finding led to a modification of the antifungal 
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medication in for 35% (44/125, medical records not 
available for 2 case-patients) of the case-patients.
Controls
The controls for the fungemia case-patients (n = 76) 
were mostly bacteremic (n = 65), but there were 5 
case-patients infected with Candida sp. Medical re-
cords were not available for 6 control case-patients. 
Median age for this group was 70 years (vs. 68 years 
for case-patients), 70% were males (versus 63% for 
the case-patients), 47% had digestive tract disease (vs. 
59% of the case-patients), and 17% had a malignancy 
(vs. 13% of the case-patients) (data were available for 
64 case-patients). Use of S. cerevisiae var. boulardii pro-
biotic by the Saccharomyces fungemia group was 43% 
compared with 5% (4/76) for the control group (odds 
ratio [OR] 14, 95% CI 4–44).
Microbes detected for controls who had non-
blood cultures (n = 123) were also mostly bacteria (n 
= 97), but Candida sp. or other yeasts (n = 51; with or 
without a concomitant bacterial finding) were more 
common than in blood cultures. Median age for this 
group was 65 years (vs. 64 years for case-patients), 
44% were males (vs. 59% for case-patients), 70% had 
digestive tract disease (vs. 69% of case-patients), and 
28% had a malignancy (vs. 38% of case-patients) 
(data on underlying diseases were available for 100 
controls). Use of S. cerevisiae var. boulardii probiotic 
was 19% (24/125) in the Saccharomyces culture-posi-
tive group compared with 2% (3/123) for the control 
group (OR 10, 95% CI 3–32).
Discussion
We report 20 cases of Saccharomyces fungemia in pa-
tients who used S. cerevisiae var. boulardii probiotic. 
These cases have increased the number of cases re-
ported in the literature by 34%.
We evaluated 125 of 1,153 patients who had a 
nonblood Saccharomyces culture finding and con-
firmed use of S. cerevisiae var. boulardii probiotic by 
19% of these case-patients. To our knowledge, the 
magnitude of findings other than fungemia has not 
been reported. Although some of these nonblood 
findings might represent colonization, positive Sac-
charomyces cultures led to a change in antimicrobial 
drugs for 44 (35%) patients who had evaluated cases.
We also evaluated use of S. cerevisiae var. boulardii 
probiotic for patients who had a Saccharomyces culture 
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Table 2. Characteristics of 46 case-patients who had Saccharomyces fungemia in 5 hospital districts, Finland, January 1, 2009‒ 
December 31, 2018* 
Characteristic Value 
No. patients 46 
Median age, y (range) 68 (30–93) 
Sex  29 (63) 
 M 29 (63) 
 F 17 (37) 
Use of S. cerevisiae var. boulardii probiotic in preceding 3 mo† 25/46 (54) 
Use of S. cerevisiae var. boulardii probiotic in preceding 7 d† 20/46 (43) 
Use of S. cerevisiae var. boulardii probiotic in preceding 7 d in control group‡ 4/76 (5) 
Central venous catheter 8 (17) 
Use of antimicrobial drugs in preceding 4 weeks 33 (72) 
Change in antimicrobial drugs because of fungemia 23 (50) 
Underlying diseases  
 Digestive tract 27 (59) 
 Neurologic 11 (24) 
 Cardiovascular 8 (17) 
 Solid tumor with metastasis 6 (13) 
 Diabetes mellitus (any type) 6 (13) 
 Pulmonary 5 (11) 
 Liver 4 (9) 
 Rheumatic 4 (9) 
 Chronic kidney§ 3 (7) 
McCabe score†  
 No or nonfatal underlying disease 22 (48) 
 Ultimately fatal underlying diseases (<5 y) 9 (20) 
 Rapidly fatal underlying diseases (<1 y) 5 (11) 
Severity of disease  
 qSOFA score >2 at time of fungemia 16 (35) 
 Septic shock at time of fungemia 6 (13) 
 Death by day 7 after fungemia 10 (22) 
*Values are no. (%) or no. positive/no. tested (%) unless otherwise indicated. 
†Medical records were not available for 10 case-patients. 
‡Medical records were not available for 6 control case-patients. 
§History of creatinine level >120 mol/L. 
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finding and compared it with that of a control group 
who had different positive blood and nonblood cul-
tures and were in the same ward around the same 
time. The Saccharomyces fungemia patients had an 
OR of 14 and nonblood culture-positive patients had 
an OR of 10 for use of this probiotic compared with 
respective controls. Moreover, case-patient 7 (Table 
1) is an example of a patient in whom probiotic use 
unequivocally caused the fungemia. The patient had 
had a percutaneous endoscopic gastrostomy feeding 
tube inserted 2 days before the fungemia, had septic 
shock, and then died. The probiotic was administered 
at least once through the tube, and the tip of the tube 
was unintentionally displaced from its ventricular 
position, leading to an accidental peritoneal applica-
tion of the probiotic.
Saccharomyces fungemias occurred most often in 
patients who had diseases of the gastrointestinal tract 
(59%). This finding is nearly identical to the amount 
reported in a meta-analysis (58%) (9). Furthermore, 
there are reports of Saccharomyces fungemias in pa-
tients not given pretreatment with a S. cerevisiae var. 
boulardii probiotic that have been believed to have 
been derived from contaminated central venous cath-
eters (26–28).
Bacteremias and fungemias have not been encoun-
tered in clinical trials with probiotics in general. There 
were probiotic studies conducted with susceptible 
patients who did not have blood culture findings and 
who had hepatic encephalopathy (29). However, seri-
ous concurrent conditions have usually been an exclu-
sion criterion; thus, the safety profile remains unclear. 
Furthermore, there are other reported safety issues 
with probiotics, such as contamination of a probiotic 
supplement with a pathogenic microbe or possible 
transfer of an antimicrobial drug resistance gene from 
a probiotic microbe to pathogenic microbes (30–32).
Regarding the benefits of probiotics, is there evi-
dence showing that adults should use S. cerevisiae 
var. boulardii probiotic in conjunction with antimicro-
bial drugs to prevent Clostridioides difficile infections 
(CDIs) that cause diarrhea? A meta-analysis during 
2017 combined S. cerevisiae var. boulardii probiotic 
studies conducted in adult populations to prevent 
CDIs (33). There were 5 studies. All studies had a low 
number of CDIs (15 cases of CDI in control groups) 
and all had nonsigficant results (pooled risk ratio 
0.63, 95% CI 0.29–1.37).
Currently, several companies sell S. cerevisiae 
var. boulardii  yeast, but total consumption of this 
yeast in Finland is not known. Thus, we are not able 
to relate our study results to its use. However, na-
tionwide consumption of probiotics does not reflect 
the risk for fungemia or nonblood culture findings, 
or use of this probiotic by susceptible patients in 
hospitals. Cautious use of S. cerevisiae var. boulardii 
probiotic in gastrointestinal surgery wards would 
probably be one of the most effective ways to de-
crease these culture findings.
Moreover, the benefits for the indication for 
which the probiotic is used need to be established. 
There are 2 recent US guidelines on administration of 
probiotics in general for primary prevention of CDI. 
The first guideline states that there are insufficient 
data to recommend the administration (34), and the 
second guideline states that in certain circumstances 
certain probiotics could be used, but the quality of 
evidence is low (35).
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University hospital district 
Total Helsinki Tampere Turku Oulu Kuopio 
Catchment area in 2017 3,310,000 1,650,000 530,000  480,000 400,000 250,000 
Inpatient days in 2017 1,814,183 784,252 307,484  294,834 191,612 236,001 
Patients who had clinical findings 1,344 649 30  215 285 165 
 Abdominal region 205 67 21  8 76 33 
 Oral or respiratory tract 676 387 6  71 137 75 
 Fecal 191 53 1  130 4 3 
 Other or unspecified 272 142 2  6 68 54 
Patients who had medical record of Saccharomyces 
cerevisiae var. boulardii probiotic per clinical finding† 
24/125 
(19) 
3/25 (12) 6/25 (24)  4/25 (16) 4/25 (16) 7/25 (28) 
 Abdominal region 15 2 4  1 4 4 
 Oral or respiratory tract 4 0 1  3 0 0 
 Other or unspecified 5 1 1  0 0 3 
Patients who had medical record of S. cerevisiae var. 
boulardii probiotic in control group 
3/123 (2) 0/25 (0) 1/25 (4)  0/23 (0) 0/25 (0) 2/25 (8) 
No. patients who had change of antimicrobial drugs 
because of finding of Saccharomyces sp.‡ 
44/125 
(35) 
11/25 (44) 3/25 (12)  8/25 (32) 13/25 (52) 9/25 (36) 
*Values are no. or no. positive/no. tested (%). 
†Fecal samples excluded. The most recent 25 case-patients per hospital district checked. Medical records not available for 6 case-patients. Kuopio last 3 
mo of probiotic use, others last 7 d. 
‡Medical records not available for 2 case-patients. 
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The first limitation of this study is that we were 
not able to obtain microbiological evidence that the 
fungal infections were caused by the S. cerevisiae var. 
boulardii probiotic strain and not by another strain. 
Furthermore, the retrospective design using medical 
records can lead to a bias in reporting. Only confirmed 
use of probiotics was reported in this study, and case-
patients whose medical records were not available 
were defined as not using a probiotic. Thus, the per-
centage of probiotic users was the minimum estimate 
in all groups. All medications given to patients in the 
wards were documented in medical records of pa-
tients, but patients might have used these medications 
before they were admitted to the hospital. Moreover, 
most patients who had fungemia were given bacterial 
antimicrobial drugs, which could have decreased the 
routine of taking blood cultures. Recall bias (e.g., the 
S. cerevisiae var. boulardii probiotic would have been 
mentioned in the medical charts more often in case-pa-
tients than in control-patients because of Saccharomyces 
culture finding) was not a limitation in this study. For 
all but 1 case-patient, the probiotic was recorded in the 
charts before the culture result was complete.
S. cerevisiae var. boulardii probiotics are not recom-
mended for patients who have indwelling catheters, 
are immunocompromised, or are critically ill. Our 
results indicate that use of S. cerevisiae var. boulardii 
probiotics should also be considered carefully for pa-
tients whose gastrointestinal tract integrity might be 
compromised. Furthermore, more data are needed to 
elucidate the health benefits of S. cerevisiae var. boular-
dii probiotics in general .
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